• The updated results were presented in poster session at the ASH annual meeting
   
• The study shows strong data for DPX-Survivac in combination with pembrolizumab

IMV Inc., a clinical-stage biopharmaceutical firm focusing on immunotherapy in oncology, recently announced updated results from SPiReL, which is an ongoing Phase 2 study of DPX-Survivac combined with pembrolizumab in patients suffering from refractory/ recurrent diffuse large B-cell lymphoma (r/r DLBCL). These updated results were presented through a poster session in Florida, at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando.

Apparently, the poster consisted of an additional data arranged between the presentation and the submission of the abstract, as it continued to show a positive therapeutic profile as well as clinical benefit for r/r DLBCL patients associated with the treatment, who had received the combination regimen of DPX-Survivac.

Lead investigator of the clinical trial, Neil Berinstein, MD, FFCPC, ABIM and a hematologist at Toronto’s Sunnybrook Health Sciences Centre commented that the updated data exhibit favorable activity in patients who were treated with a combination regimen of DPX-Survivac for refractory/ recurrent diffuse large B-cell lymphoma.

Berinstein further added that as a contrast to both standard-of-care treatments as well as various other immunotherapeutic approaches for development, observation of the clinical advantage besides a safety profile shows the potential of DPX-Survivac to be able to reach out to a population of patients in a dire need of better options for treatment.

Chief Medical Officer at IMV, Joanne Schindler, M.D., D.V.M., stated that the results show a sturdy response in patients getting evaluated who followed the combination regimen consisting DPX-Survivac. It has continued to show a positive therapeutic profile especially for patients who were suffering from hard-to-treat cancers.

Schindler continued that the data validates the novel mechanism of DPX-Survivac that extends the earlier documented results for solid cancers to now surviving-expressing hematologic diseases. The company believes that it represents a meaningful alternative to chemotherapy regimens that are more toxic. The company is looking forward to obtaining topline results from the study as it prepares to introduce IMV-sponsored study in 2020 for r/r DLBCL.

Source Credit- https://ir.imv-inc.com/news-releases/news-release-details/updated-clinical-data-phase-2-spirel-study-evaluating-dpx